Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

Stopped early · Not applicable

Conditions studied: Pulmonary Hypertension

In brief

The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.

Key facts

Study ID

NCT02220634

Run by

National Jewish Health

People needed

10

Starts

2014-08-01

Expected to finish

2017-05-25

Last updated by the study team

2021-01-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years old
• Diagnosis of RHC-proven PH
• Mean pulmonary artery pressure (mPAP) > 25 mmHg
• Pulmonary vascular resistance (PVR) > 3 woods units
• Pulmonary capillary wedge pressure (PCWP) < 15 mmHg).

You may not qualify if…

• Second- or third-degree AV block or sinus node dysfunction
• Known hypersensitivity to adenosine or regadenoson
• Systolic blood pressure < 90mm Hg
• Active bronchospasm
• Autonomic dysfunction as defined by prior diagnosis of:
• Postural Orthostatic Tachycardia Syndrome (POTS)
• Neurocardiogenic Syncope (NCS)
• Neurally Mediated Hypotension (NMH)
• Vasovagal Syncope
• Hypovolemia
• > 40% Left main coronary stenosis
• Moderate or > valvular stenosis
• Pericarditis/pericardial effusions
• > 70% carotid artery stenosis
• Positive urine pregnancy test

Where it is running

• National Jewish Health — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.